Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India

View Full Paper
Ask AI
Bookmark
Share

Authors

PSParas SatadeveAGAdamya GuptaSSSashi Singh

Discussion

Loading...

Member takes

Overview

Real-world data reveals treatment outcomes after venetoclax plus decitabine in Acute Myeloid Leukemia, indicating significant toxicity and effectiveness.

Key Points

  • 46% of AML patients achieved complete remission after two cycles of venetoclax plus decitabine therapy.
  • The study reported a median overall survival of 17 months with significant incidences of myelosuppression and complications.
  • Analysis involved treatment outcomes from a cohort receiving venetoclax with hypomethylating therapy at a single center in India.
  • Findings underscore the need for rigorous support due to high non-hematological toxicities like tumor lysis syndrome and infections.

Cite This Study

Satadeve et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d554https://doi.org/10.1182/blood-2025-7043
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial2025
  2. 2Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  3. 3Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia2025 · 1 citations
  4. 4Efficacy of a 14-day venetoclax regimen in combination with a hypomethylating agent for Acute Myeloid Leukemia: A single-center retrospective analysis2025
  5. 5Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia2025